Prostaglandin E2 → 16,16-Dimethylprostaglandin E

HRID 437107

反応式

HRID 437107 の反応式
CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(O)=O)C(=O)C[C@H]1O.[CH3:26][CH2:27][CH2:28][CH2:29][C:30]([C@H:33]([OH:52])/[CH:34]=[CH:35]/[C@@H:36]1[C@@H:41]([CH2:42]/[CH:43]=[CH:44]\[CH2:45][CH2:46][CH2:47][C:48]([OH:50])=[O:49])[C:39](=[O:40])[CH2:38][C@H:37]1[OH:51])([CH3:32])[CH3:31]>>[CH3:26][CH2:27][CH2:28][CH2:29][C:30]([C@H:33]([OH:52])/[CH:34]=[CH:35]/[C@@H:36]1[C@@H:41]([CH2:42][CH2:43][CH2:44][CH2:45][CH2:46][CH2:47][C:48]([OH:50])=[O:49])[C:39](=[O:40])[CH2:38][C@H:37]1[OH:51])([CH3:32])[CH3:31]

参加物

3

反応物 2

HCID 5280360Prostaglandin E2HCID 528306616,16-Dimethyl-pge2

生成物 1

HCID 528305816,16-Dimethylprostaglandin E

実験手順

Further, following the procedure of Preparation 16, but using in place of the C-15 unsubstituted PGE2 -type compound of Preparation 16 and above, the 15-methyl and 15-methyl ether PGE2 -type compounds described above, there are obtained the corresponding 15-methyl and 15-methyl ether PGE1 -type compounds of either 15-epimeric configuration in both free acid and methyl ester form. Further, following the procedure of Preparation 16 but using in place of the C-16 unsubstituted PGE2 -type compound therein the 16-methyl or 16,16-dimethyl-PGE2 -type compounds described above there are obtained the corresponding 16-methyl or 16,16-dimethyl-PGE1 -type compounds of this invention. Finally, following the procedure of Preparation 16, but using the various 17-substituted phenyl PGE2 -type compounds described above there are obtained the corresponding 17-substituted phenyl-PGE1 -type compounds. The compounds in this paragraph represent the nvel PGE1 -type compounds of this invention.

後処理

  1. customthe procedure of Preparation 16

出典と根拠

ORDレコード
ord-9bb4331f5b84424f91f7cbe19b802e63
出典データセット
uspto-grants-1977_06
特許番号
US04029693

関連ノート

読み込み中…